159 related articles for article (PubMed ID: 38633130)
1. Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice-site
Mason G; Aghajani R; Dance B; Othman J; Goodwin L; Stevenson W; Mackinlay N
EJHaem; 2024 Apr; 5(2):397-402. PubMed ID: 38633130
[TBL] [Abstract][Full Text] [Related]
2. Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.
Pathak A; Pemov A; McMaster ML; Dewan R; Ravichandran S; Pak E; Dutra A; Lee HJ; Vogt A; Zhang X; Yeager M; Anderson S; Kirby M; ; ; Caporaso N; Greene MH; Goldin LR; Stewart DR
Hum Genet; 2015 Jul; 134(7):775-87. PubMed ID: 25939664
[TBL] [Abstract][Full Text] [Related]
3. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
[TBL] [Abstract][Full Text] [Related]
4. Transient immune deficiency accompanied with homozygous CBL rare variant.
Morishita A; Yeh TW; Tomari K; Furuichi M; Kashimada K; Morio T; Takagi M; Imai K
Pediatr Int; 2023 Jan; 65(1):e15439. PubMed ID: 36495474
[TBL] [Abstract][Full Text] [Related]
5. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
6. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
7. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission of infantile Takayasu arteritis associated with germline CBL syndrome after allogeneic hematopoietic stem cell transplantation: A case report and literature review.
Munoz-Osores E; Piñones M; Barriga F; Wietstruck MA; Pérez-Mateluna G; Mellado C; Aracena M; Parra R; García C; Borzutzky A
Transpl Immunol; 2024 Apr; 83():102013. PubMed ID: 38395087
[TBL] [Abstract][Full Text] [Related]
9. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
[TBL] [Abstract][Full Text] [Related]
10. Hydrops, fetal pleural effusions and chylothorax in three patients with CBL mutations.
Bülow L; Lissewski C; Bressel R; Rauch A; Stark Z; Zenker M; Bartsch O
Am J Med Genet A; 2015 Feb; 167A(2):394-9. PubMed ID: 25358541
[TBL] [Abstract][Full Text] [Related]
11. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
Pérez B; Mechinaud F; Galambrun C; Ben Romdhane N; Isidor B; Philip N; Derain-Court J; Cassinat B; Lachenaud J; Kaltenbach S; Salmon A; Désirée C; Pereira S; Menot ML; Royer N; Fenneteau O; Baruchel A; Chomienne C; Verloes A; Cavé H
J Med Genet; 2010 Oct; 47(10):686-91. PubMed ID: 20543203
[TBL] [Abstract][Full Text] [Related]
14. Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants.
Baccelli F; Leardini D; Muratore E; Messelodi D; Bertuccio SN; Chiriaco M; Cancrini C; Conti F; Castagnetti F; Pedace L; Pession A; Yoshimi A; Niemeyer C; Tartaglia M; Locatelli F; Masetti R
Hum Genomics; 2022 Sep; 16(1):40. PubMed ID: 36123612
[TBL] [Abstract][Full Text] [Related]
15. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
16. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
[TBL] [Abstract][Full Text] [Related]
17. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
18. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
[TBL] [Abstract][Full Text] [Related]
19. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia.
Hecht A; Meyer JA; Behnert A; Wong E; Chehab F; Olshen A; Hechmer A; Aftandilian C; Bhat R; Choi SW; Chonat S; Farrar JE; Fluchel M; Frangoul H; Han JH; Kolb EA; Kuo DJ; MacMillan ML; Maese L; Maloney KW; Narendran A; Oshrine B; Schultz KR; Sulis ML; Van Mater D; Tasian SK; Hofmann WK; Loh ML; Stieglitz E
Haematologica; 2022 Jan; 107(1):178-186. PubMed ID: 33375775
[TBL] [Abstract][Full Text] [Related]
20. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S; Bacher U; Alpermann T; Reiter A; Ulke M; Dicker F; Eder C; Kohlmann A; Grossmann V; Kowarsch A; Kern W; Haferlach C; Haferlach T
Haematologica; 2012 Dec; 97(12):1890-4. PubMed ID: 22733026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
